FDA premarket approval records identify Boston Scientific Corp as the applicant behind two device families in the current filing set: the Vercise Deep Brain Stimulation (DBS) Systems, regulated as an implanted electrical stimulator for parkinsonian symptoms under product code NHL, and the ROTAPRO Rotational Atherectomy System, a coronary atherectomy catheter under product code MCX. The filings are supplements to existing approvals rather than original applications, and their scope is largely manufacturing and labeling rather than new clinical indications. The applicant address on the Vercise records is 25155 Rye Canyon Loop, Valencia, California, and on the ROTAPRO records Two Scimed Pl., Maple Grove, Minnesota; these are filing addresses, not statements of corporate headquarters. [1][2][5]
Vercise DBS supplements in October 2026
Two Vercise DBS supplements appear in the record. P150031/S100, a Special (Immediate Track) supplement received September 15, 2026 and decided October 15, 2026, covers a labeling change: additional guidance in the Clinician Programmer feature for implantable pulse generator battery recharge interval and non-rechargeable battery longevity estimates. P150031/S102, a 30-Day Notice received September 30, 2026 and decided October 30, 2026, covers a process change to raise the mold temperature used in injection molding of the seal stack component. Both were decided without expedited review. [5][1]
Boston Scientific’s product page lists 16-contact Vercise Cartesia X and Cartesia HX directional leads for the Vercise Genus Deep Brain Stimulation System. It also lists Vercise Genus IPGs, leads, a VN5 programmer and a DBS patient programmer among the system components. The surgical implant manual covers the Vercise Genus, Vercise Gevia and Vercise PC systems. The manufacturer’s indications page links to the Instructions for Use for contraindications, warnings and potential adverse events. [6][9][10]
ROTAPRO process and design supplements
Three ROTAPRO supplements were decided in October 2026. P900056/S226, a Real-Time Process supplement received July 23, 2026 and approved October 21, 2026, covers a design change to a component of the Pneumatic Kit for the ROTAPRO console. P900056/S228, a 30-Day Notice received September 22, 2026 and decided October 20, 2026, covers updates to the printed circuit board assembly adhesive inspection process and new adhesive dispensers. P900056/S229, a 30-Day Notice received September 24, 2026 and decided October 21, 2026, covers changes to PCBA soldering and strain relief fixtures. [2][4][3]
What the filing set shows and does not show
The linked collection holds 16 premarket approval records, all on the PMA pathway, with decisions of 10 approvals and 6 30-day notices as of the snapshot date. The five-record sample shown here contains three 30-day notices and two approvals; the sample is explicitly smaller than the collection, so its mix should not be read as the full portfolio's composition. These counts describe the linked filings only, not company sales, total device portfolio or safety performance. [1][2][3][4][5]
The record supports a narrow reading: Boston Scientific Corp is the named applicant on supplements for two Class 3 device families, with recent activity concentrated in manufacturing process notices and one labeling supplement. No recall records appear in the linked set. Details beyond the filing scope, such as commercial availability, clinical performance or corporate ownership of any brand, are not established by these documents. [1][2][5]










